Achieving PSA < 0.2 ng/ml before Radiation Therapy Is a Strong Predictor of Treatment Success in Patients with High-Risk Locally Advanced Prostate Cancer

Table 1

Patient and treatment characteristics, compared between patients with a pre-RT PSA <0.2 ng/ml and ≥0.2 ng/ml.

Variables	All	Pre-RT PSA < 0.2	Pre-RT PSA ≥ 0.2
	()	()	()
Age [y.o.], median (range)	71 (57–83)	71 (57–83)	71 (58–82)
Initial PSA [ng/ml], median (range)	24.7 (1.9–282.5)	20.3 (1.9–268)	31.0 (5.33–282.5)
Clinical T stage, (%)
T1	36 (17.7)	18 (17.1)	18 (8.2)
T2	38 (18.6)	17 (16.2)	21 (21.2)
T3	123 (60.3)	68 (64.8)	55 (55.6)
T4	7 (3.4)	2 (1.9)	5 (5.0)
Gleason score, (%)
7 or less	73 (35.8)	34 (32.4)	39 (39.3)
8 or higher	131 (64.2)	71 (67.6)	60 (60.7)
No. NCCN high risk factor, (%)
1	85 (41.7)	45 (42.9)	40 (40.4)
2 or 3	119 (58.3)	60 (57.1)	59 (59.6)
LH-RH agonist + bicalutamide, (%)
Yes	142 (69.6)	95 (90.5)	47 (47.5)
No	62 (30.4)	10 (95)	52 (52.5)
Follow-up period [mo], median (IQR)	113 (95–128)
Neoadjuvant HT [mo], median (IQR)	7 (6–10)
Total HT [mo], median (IQR)	27 (14–38)
PSA before RT [ng/ml], median (range)	0.20 (0.01–22.1)